This study assesses the epidemiologic situation of chlamydia trachomatis, its complications and long term sequalae and related healthcare resource utilization and costs among adults in Germany. The study is a retrospective cohort study based on German Statutory Health Insurance (SHI) claims data for adolescents and adults aged 14 to 44 years in the years 2008-2022 with documented (confirmed) diagnosis of CT. Study Objectives are to: 1. Estimate frequency of potential short-term complications and long-term sequelae in patients with medically attended chlamydia infection 2. Analyze time from first documented prevalent CT infection to first potential complication/sequelae diagnosis 3. Estimate frequency of re-infection (chlamydia recurrence) and co-infections with other sexually transmitted infections (STIs) in patients with medically-attended chlamydia infection 4. Estimate absolute healthcare resource utilization (by level of care and specialty) and costs in patients with chlamydia infection, including for potential short-term complications and long-term sequelae 5. Estimate administrative prevalence of medically-attended chlamydia infection in the overall study population 6. Estimate administrative prevalence of diagnoses potentially associated with a chlamydia infection (i.e., short-term complications/long-term sequelae) in the overall study population 7. Estimate frequency of chlamydia testing in the overall study population
Study Type
OBSERVATIONAL
Enrollment
81,239
Unnamed facility
Germany, Germany
Number of female participants with documented (confirmed) outpatient or any inpatient of pelvic inflammatory disease (PID)
The absolute frequency of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases
Time frame: From Year 2008 to Year 2022
Number of female participants with documented confirmed outpatient or any inpatient diagnosis of ectopic pregnancy
The absolute frequency of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases
Time frame: From Year 2008 to Year 2022
Number of female participants with documented confirmed outpatient or any inpatient diagnosis tubal factor infertility
The absolute frequency of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases
Time frame: From Year 2008 to Year 2022
Number of male participants with documented confirmed outpatient or any inpatient diagnosis of orchitis or epididymitis
The absolute frequency of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases
Time frame: From Year 2008 to Year 2022
Number of male participants with documented confirmed outpatient or any inpatient diagnosis of proctitis
The absolute frequency of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases
Time frame: From Year 2008 to Year 2022
Number of male participants with documented confirmed outpatient or any inpatient diagnosis of prostatitis
The absolute frequency of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases
Time frame: From Year 2008 to Year 2022
Number of male and female participants with documented confirmed outpatient or any inpatient diagnosis of female/male infertility
The absolute frequency of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases
Time frame: From Year 2008 to Year 2022
Number of male and female participants with documented confirmed outpatient or any inpatient diagnosis of Urethritis and urethral syndrome
The absolute frequency of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases
Time frame: From Year 2008 to Year 2022
Time in days from first documented prevalent CT infection to first documented complication/sequelae diagnosis
This time-to-event analysis will use the Kaplan-Meier method to estimate the median time-to-event in the presence of censoring
Time frame: From Year 2008 to Year 2022
Number of male and female participants with confirmed outpatient or any inpatient CT diagnosis at least 30 days after last CT diagnosis of any kind (reinfection)
The absolute number of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases.
Time frame: From Year 2008 to Year 2022
Number of CT reinfections/episodes
The absolute number of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases.
Time frame: From Year 2008 to Year 2022
Number of male and female participants with documented confirmed outpatient or any inpatient diagnosis of other STI
The absolute number of documented cases will be reported. The relative frequency will be computed as the proportion of patients under exposure (first documented prevalent CT infection) which become cases.
Time frame: From Year 2008 to Year 2022
Cost incurred from the number of physician contacts (of any specialty)
Costs are summed up per patient for the specified follow-up time
Time frame: From Year 2008 to Year 2022
Costs incurred from the number of hospital admissions
Costs are summed up per patient for the specified follow-up time
Time frame: From Year 2008 to Year 2022
Costs incurred for the number of prescriptions filled for any drug
Costs are summed up per patient for the specified follow-up time
Time frame: From Year 2008 to Year 2022
Costs incurred for the number of filled prescriptions for any medical aid
Costs are summed up per patient for the specified follow-up time
Time frame: From Year 2008 to Year 2022
Costs incurred for the number of physician contacts (of any specialty) related to CT or STI-diagnoses.
Costs are summed up per patient for the specified follow-up time
Time frame: From Year 2008 to Year 2022
Costs incurred for the number of hospital admissions related to CT or STI-diagnoses.
Costs are summed up per patient for the specified follow-up time
Time frame: From Year 2008 to Year 2022
Costs incurred for the number of filled prescriptions for CT-related antibiotics, dispensed within 30 days after CT diagnosis
Costs are summed up per patient for the specified follow-up time and numbers for each ATC code will be reported separately and in aggregated form
Time frame: From Year 2008 to Year 2022
Costs incurred for the number of filled prescriptions for medical aids related to CT or STI diagnoses
Costs are summed up per patient for the specified follow-up time
Time frame: From Year 2008 to Year 2022
Total CT-/STI-unspecific health care costs (inpatient, outpatient, drugs, medical aids)
Costs are summed up per patient for the specified follow-up time
Time frame: From Year 2008 to Year 2022
CT-/STI-unspecific outpatient costs
Costs are summed up per patient for the specified follow-up time
Time frame: From Year 2008 to Year 2022
CT-/STI-unspecific inpatient costs
Costs are summed up per patient for the specified follow-up time
Time frame: From Year 2008 to Year 2022
CT-/STI-unspecific drug cost
Costs are summed up per patient for the specified follow-up time
Time frame: From Year 2008 to Year 2022
CT-/STI-unspecific medical aid costs
Costs are summed up per patient for the specified follow-up time
Time frame: From Year 2008 to Year 2022
Outpatient costs that are related to cases with a confirmed CT diagnosis
Costs are summed up per patient for the specified follow-up time
Time frame: From Year 2008 to Year 2022
Inpatient costs that are related to cases with any CT diagnosis
Costs are summed up per patient for the specified follow-up time
Time frame: From Year 2008 to Year 2022
Outpatient costs that are related to cases with any confirmed STI diagnosis
Costs are summed up per patient for the specified follow-up time
Time frame: From Year 2008 to Year 2022
Inpatient costs that are related to cases with any confirmed STI diagnosis
Costs are summed up per patient for the specified follow-up time
Time frame: From Year 2008 to Year 2022
Costs of potentially CT-relevant antibiotics dispensed up to 30 days after confirmend outpatient or any inpatient CT diagnosis
Costs are summed up per patient for the specified follow-up time
Time frame: From Year 2008 to Year 2022
Confirmed outpatient or any inpatient CT diagnosis
The absolute number of prevalent cases per calendar year will be reported for each outcome. Due to the possibility of multiple infections per person the number of affected individuals will also be reported. The relative frequency will be computed as the proportion of patients which become cases
Time frame: From Year 2008 to Year 2022
Confirmed outpatient or any inpatient of PID (CT associated, or other origin) in females
The absolute number of prevalent cases per calendar year will be reported for each outcome. Due to the possibility of multiple infections per person the number of affected individuals will also be reported. The relative frequency will be computed as the proportion of patients which become cases
Time frame: From Year 2008 to Year 2022
First documented confirmed outpatient or any inpatient diagnosis of ectopic pregnancy in females
The absolute number of prevalent cases per calendar year will be reported for each outcome. Due to the possibility of multiple infections per person the number of affected individuals will also be reported. The relative frequency will be computed as the proportion of patients which become cases
Time frame: From Year 2008 to Year 2022
First documented confirmed outpatient or any inpatient diagnosis tubal factor infertility in females
The absolute number of prevalent cases per calendar year will be reported for each outcome. Due to the possibility of multiple infections per person the number of affected individuals will also be reported. The relative frequency will be computed as the proportion of patients which become cases
Time frame: From Year 2008 to Year 2022
First documented confirmed outpatient or any inpatient diagnosis of orchitis or epididymitis in males
The absolute number of prevalent cases per calendar year will be reported for each outcome. Due to the possibility of multiple infections per person the number of affected individuals will also be reported. The relative frequency will be computed as the proportion of patients which become cases
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: From Year 2008 to Year 2022
First documented confirmed outpatient or any inpatient diagnosis of proctitis in males
The absolute number of prevalent cases per calendar year will be reported for each outcome. Due to the possibility of multiple infections per person the number of affected individuals will also be reported. The relative frequency will be computed as the proportion of patients which become cases
Time frame: From Year 2008 to Year 2022
First documented confirmed outpatient or any inpatient diagnosis of prostatitis in males
The absolute number of prevalent cases per calendar year will be reported for each outcome. Due to the possibility of multiple infections per person the number of affected individuals will also be reported. The relative frequency will be computed as the proportion of patients which become cases
Time frame: From Year 2008 to Year 2022
First documented confirmed outpatient or any inpatient diagnosis of infertility in males
The absolute number of prevalent cases per calendar year will be reported for each outcome. Due to the possibility of multiple infections per person the number of affected individuals will also be reported. The relative frequency will be computed as the proportion of patients which become cases
Time frame: From Year 2008 to Year 2022
First documented confirmed outpatient or any inpatient diagnosis of Urethritis and urethral syndrome in males
The absolute number of prevalent cases per calendar year will be reported for each outcome. Due to the possibility of multiple infections per person the number of affected individuals will also be reported. The relative frequency will be computed as the proportion of patients which become cases
Time frame: From Year 2008 to Year 2022
Number of male and female participants with documented CT test (screening)
The absolute number of tests as well as the absolute and relative frequency of tested individuals will be reported
Time frame: From Year 2008 to Year 2022
Number of male and female participants with documented CT tests (diagnostic/curative)
The absolute number of tests as well as the absolute and relative frequency of tested individuals will be reported
Time frame: From Year 2008 to Year 2022